CS259891B2 - Method of crystalline thorasemide preparation in pure modification i - Google Patents

Method of crystalline thorasemide preparation in pure modification i Download PDF

Info

Publication number
CS259891B2
CS259891B2 CS865945A CS594586A CS259891B2 CS 259891 B2 CS259891 B2 CS 259891B2 CS 865945 A CS865945 A CS 865945A CS 594586 A CS594586 A CS 594586A CS 259891 B2 CS259891 B2 CS 259891B2
Authority
CS
Czechoslovakia
Prior art keywords
modification
torasemide
preparation
pure
water
Prior art date
Application number
CS865945A
Other languages
Czech (cs)
English (en)
Other versions
CS594586A2 (en
Inventor
Fritz Topfmeier
Gustav Lettenbauer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of CS594586A2 publication Critical patent/CS594586A2/cs
Publication of CS259891B2 publication Critical patent/CS259891B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CS865945A 1985-08-17 1986-08-11 Method of crystalline thorasemide preparation in pure modification i CS259891B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853529529 DE3529529A1 (de) 1985-08-17 1985-08-17 Verfahren zur herstellung einer stabilen modifikation von torasemid

Publications (2)

Publication Number Publication Date
CS594586A2 CS594586A2 (en) 1988-03-15
CS259891B2 true CS259891B2 (en) 1988-11-15

Family

ID=6278766

Family Applications (2)

Application Number Title Priority Date Filing Date
CS865945A CS259891B2 (en) 1985-08-17 1986-08-11 Method of crystalline thorasemide preparation in pure modification i
CS914199A CS419991A3 (en) 1985-08-17 1991-12-31 Pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
CS914199A CS419991A3 (en) 1985-08-17 1991-12-31 Pharmaceutical preparations

Country Status (25)

Country Link
US (4) US4743693A (sv)
EP (1) EP0212537B1 (sv)
JP (2) JPS6245576A (sv)
KR (1) KR930009818B1 (sv)
AU (1) AU573454B2 (sv)
CA (1) CA1307277C (sv)
CS (2) CS259891B2 (sv)
DD (1) DD259858A5 (sv)
DE (2) DE3529529A1 (sv)
DK (1) DK162518C (sv)
ES (1) ES2001522A6 (sv)
FI (1) FI82189C (sv)
GR (1) GR862139B (sv)
HK (1) HK59994A (sv)
HU (1) HU195778B (sv)
IE (1) IE59237B1 (sv)
IL (1) IL79672A (sv)
LT (1) LT3596B (sv)
NO (1) NO170079C (sv)
NZ (1) NZ217172A (sv)
PL (1) PL146086B1 (sv)
PT (1) PT83186B (sv)
SU (1) SU1480766A3 (sv)
UA (1) UA7080A1 (sv)
ZA (1) ZA866151B (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
US5166162A (en) * 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
JP3586471B2 (ja) * 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 トラセミド含有医薬組成物
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US20030026835A1 (en) * 1999-02-15 2003-02-06 Sumitomo Pharmaceuticals Company Limited Tablets disintegrating rapidly in the oral cavity
CZ2002404A3 (cs) 1999-08-11 2002-06-12 Teva Pharmaceutical Industries Ltd. Polymorfní formy torsemidu
DE1292303T1 (de) 2000-02-17 2003-09-18 Teva Pharma Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
US6635765B2 (en) 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192178B (sv) * 2001-08-03 2004-03-06 Ranbaxy Lab
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
PT1465890E (pt) * 2002-11-18 2007-05-31 Teva Pharma Lansoprazole estável contendo mais de 500 ppm, até cerca de 3000 ppm de água e mais de 200 ppm, até cerca de 5000 de álcool
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
US10178893B1 (en) * 2013-06-14 2019-01-15 Scott Bradley Baker Shoe
FR3018688A1 (fr) * 2014-03-19 2015-09-25 Virbac Utilisation de torasemide a faible dose dans une composition veterinaire
EP3031471A1 (en) 2014-12-12 2016-06-15 Ceva Sante Animale Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals
US12048677B2 (en) 2014-12-12 2024-07-30 Ceva Sante Animale Compositions and uses thereof for the treatment of heart failure in domestic animals
DK3173075T3 (en) * 2015-11-27 2019-01-21 Accupharma Spolka Z Ograniczona Odpowiedzialnoscia PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) * 1860-11-13 Improvement in fire-escapes
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
GB1593609A (en) * 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
LU85193A1 (fr) * 1984-01-31 1985-09-12 Christiaens Sa A Nouveaux derives de la 4-phenylaminopyridine,leur utilisation et leur preparation

Also Published As

Publication number Publication date
CS594586A2 (en) 1988-03-15
NO170079C (no) 1992-09-09
UA7080A1 (uk) 1995-06-30
DK385586A (da) 1987-02-18
NZ217172A (en) 1989-02-24
NO863305D0 (no) 1986-08-15
SU1480766A3 (ru) 1989-05-15
KR930009818B1 (ko) 1993-10-11
HK59994A (en) 1994-07-08
LTIP898A (en) 1995-03-27
DK385586D0 (da) 1986-08-13
DE3529529A1 (de) 1987-02-19
USRE34580E (en) 1994-04-05
US4822807A (en) 1989-04-18
DE3529529C2 (sv) 1987-05-27
LT3596B (en) 1995-12-27
JPH0415205B2 (sv) 1992-03-17
US4743693A (en) 1988-05-10
NO170079B (no) 1992-06-01
AU573454B2 (en) 1988-06-09
PL261052A1 (en) 1987-11-02
IE862179L (en) 1987-02-17
HU195778B (en) 1988-07-28
FI82189C (sv) 1991-02-11
DK162518B (da) 1991-11-11
AU6105586A (en) 1987-02-19
PT83186A (de) 1986-09-01
JPH02191255A (ja) 1990-07-27
EP0212537A1 (de) 1987-03-04
CS419991A3 (en) 1992-06-17
PL146086B1 (en) 1988-12-31
GR862139B (en) 1986-12-30
ZA866151B (en) 1987-04-29
EP0212537B1 (de) 1990-01-03
DD259858A5 (de) 1988-09-07
IL79672A0 (en) 1986-11-30
FI863305A (fi) 1987-02-18
ES2001522A6 (es) 1988-06-01
IE59237B1 (en) 1994-01-26
DK162518C (da) 1992-03-30
FI863305A0 (fi) 1986-08-15
FI82189B (fi) 1990-10-31
JPS6245576A (ja) 1987-02-27
DE3667970D1 (de) 1990-02-08
JPH0643400B2 (ja) 1994-06-08
NO863305L (no) 1987-02-18
HUT42069A (en) 1987-06-29
USRE34672E (en) 1994-07-26
CA1307277C (en) 1992-09-08
PT83186B (pt) 1988-07-01
KR870002076A (ko) 1987-03-30
IL79672A (en) 1990-01-18

Similar Documents

Publication Publication Date Title
CS259891B2 (en) Method of crystalline thorasemide preparation in pure modification i
CA2424462C (en) Clavulanic acid pharmaceutical compositions
GB2114969A (en) Penicillins
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
EP0067666B1 (en) Salts of antimicrobial naphthyridine and quinoline compounds and their production
IL101358A (en) Tiagabine hydrochloride crystalline monohydrate, its preparation and pharmaceutical preparations containing the same
US2474758A (en) Complex salts of streptothricin
CN106187921A (zh) 一种格列吡嗪结晶的制备方法
CA2007367C (en) Process and composition for the purification of amphotericin b
CA1178574A (en) Method for producing chemical compounds
CZ284837B6 (cs) 3/2 hydrát a anhydrát 7-/(7-(S)-amino-5-azaspiro/2.4/-heptan-5-yl/-8-chlor-6-fluor-1-/(1R,2S)-2-fluorcyklopropyl/-4-oxo-1,4-dihydrochinolin-3-karboxylové kyseliny, způsoby selektivní výroby 3/2 hydrátu, jeho krystaly a antibakteriální činidla na jeho bázi
CA1221367A (en) Fine crystalline isoxicam
JPS5885892A (ja) 新規な結晶性３−セフエム−４−カルボン酸塩および精製法
WO2015149638A1 (zh) 达比加群酯甲磺酸盐晶型、其制备方法以及药物组合物
RU2034844C1 (ru) Способ получения гидрата 8-хлор-1-метил-6-фенил-4h-1,2,4-триазоло(4,3-a) (1,4)-бензодиазепина
DE4035595C2 (de) Tafel- bzw. plättchenförmiges 8-Chlor-1-methyl-6-phenyl-4H-1,2,4-triazolo[4,3-a][1,4]benzodiazepin-Dihydrat, Verfahren zu seiner Herstellung und dessen Verwendung für "per os"-applizierbare Arzneiformen
US3142680A (en) chcij
CN117820297A (zh) 一种托吡司特的精制方法
JP2000212168A (ja) ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
JPH0673085A (ja) デカプラニン塩溶液および結晶デカプラニン塩ならびにそれらの調製方法
DE20321227U1 (de) Isostrukturelle Pseudopolymorphe von 9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin A
CZ279879B6 (cs) Způsob dělení směsi L-(-)- a DL-(-+)-efedrinu s vysokým obsahem racemátu
PL195390B1 (pl) Otrzymywanie estru 1-acetoksyetylowego cefuroksymu

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20010811